Rena Therapeutics Inc. / レナセラピューティクス株式会社

Rena Therapeutics Inc. was established in January 2015 with the aim of accelerating the practical application of the groundbreaking nucleic acid pharmaceutical technology known as Hetero Double-Stranded Nucleic Acid Technology. In February of the same year, we were granted the title of university-launched venture by Tokyo Medical and Dental University. Hetero Double-Stranded Nucleic Acid Technology is Japan’s third novel nucleic acid pharmaceutical with high universality, applicability, and scalability. It enabled, for the first time, gene control in organs other than the liver via systemic administration, which had been the major obstacle in the clinical application of nucleic acid pharmaceuticals, by conjugating ligands tailored to the target. The advantage of nucleic acid pharmaceuticals lies in the ability to design drug compounds based on the sequence information of the target genes once the mechanisms related to the genes targeted for treatment are elucidated. In the future, personalized medicine will be possible by designing drugs tailored to the genetic sequences of individual patients. Our company aims to deliver therapeutic drugs to patients as soon as possible by providing solutions tailored to the needs of our customers using Hetero Double-Stranded Nucleic Acid and various ligands and contributing to the creation of new nucleic acid pharmaceuticals.